AMGN's MariTide: Can Convenience Drive its Obesity Market Share?

Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.

Zacks Investment Research • Sep 4, 2026

Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Dogs Of The Dow: No Buys And Few Worth Watching

Dogs of the Dow remain generally overvalued, with none meeting the ideal 'fair price' threshold where dividends from $1K invested exceed share price. Analyst forecasts project 22.15% to 47.11% net gains for the top ten Dow Dogs by September 2027, with an average estimated gain of 28.46%. Yield-based strategies favor underdogs, but current market conditions suggest waiting for significant price pullbacks or dividend increases to achieve optimal entry points.

Seeking Alpha • Sep 3, 2026

AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif., Sept. 2, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m.

PRNewsWire • Sep 2, 2026

UK regulator suspends Amgen's Tavneos for new patients over unreliable data

Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying ​the main study supporting its approval was unreliable.

Reuters • Sep 1, 2026

Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs

Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.

24/7 Wall Street • Sep 1, 2026

Trump administration to announce drug pricing deals

U.S. President Donald ​Trump is expected to announce a new round of drug-pricing agreements on Monday, a White ‌House official said, part of a push to make healthcare more affordable for Americans.

Reuters • Aug 31, 2026

One Of Amgen's Biggest Moneymakers Cuts The Risk Of Dying By 20%

Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.

Investors Business Daily • Aug 31, 2026

AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE

Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Global Real-World Analyses Show Persistent Gaps in Lipid Management, With Many High-Risk Patients Undertreated and Not Achieving Recommended LDL-C Goals THOUSAND OAKS, Calif., Aug. 31, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new findings showing Repatha® (evolocumab) reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein cholesterol (LDL-C)-lowering treatments.

PRNewsWire • Aug 31, 2026

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion in free cash flow for fiscal 2025.

The Motley Fool • Aug 29, 2026